Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $58.76 million versus the consensus estimate of $52.06 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.